DRAK2 Antikörper (C-Term)

Produktnummer ABIN1882073

Es sind 3+ Publikationen für dieses Produkt verfügbar. Der Kaninchen Polyklonal anti-DRAK2 Antikörper wird verwendet zum Nachweis von DRAK2 in Proben von Human und Maus. Er wurde validiert für WB, IHC (p) und IF.

Kurzübersicht für DRAK2 Antikörper (C-Term) (ABIN1882073)

Target: DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser DRAK2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF)

Klon: RB3049

Produktdetails anti-DRAK2 Antikörper

Bindungsspezifität: AA 342-371, C-Term

Aufreinigung: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This DRAK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 342-371 amino acids from the C-terminal region of human DRAK2.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: IF: 1:10~50. WB: 1:1000. IHC-P: 1:50~100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Haltbarkeit: 6 months

Referenzen für anti-DRAK2 Antikörper (ABIN1882073)

Mao, Luo, Han, Bertrand, Wu: "Drak2 is upstream of p70S6 kinase: its implication in cytokine-induced islet apoptosis, diabetes, and islet transplantation." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 182, Issue 8, pp. 4762-70, (2009) (PubMed).

Mao, Qiao, Luo, Wu: "Transgenic drak2 overexpression in mice leads to increased T cell apoptosis and compromised memory T cell development." in: The Journal of biological chemistry, Vol. 281, Issue 18, pp. 12587-95, (2006) (PubMed).

Sanjo, Kawai, Akira: "DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis." in: The Journal of biological chemistry, Vol. 273, Issue 44, pp. 29066-71, (1998) (PubMed).

Details zu DRAK2

Target: DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Andere Bezeichnung: DRAK2

Hintergrund: DRAK2 is a novel serine/threonine kinase that induces apoptosis via catalytic activity. DRAKs present high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases. DRAK2 is located in nucleus, and the messenger RNA is ubiquitously expressed in human tissues.

Molekulargewicht: 42344

NCBI Accession: NP_004217

UniProt: O94768